Concert pharmaceuticals, inc. (CNCE)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue:
License and research and development revenue

1,077

10,505

143,891

174

-

-

-

-

License and research and development revenue

-

-

-

-

6,574

6,576

23,408

11,349

Other revenue (Note 14 and Note 13)

-

-

-

-

50,155

0

0

-

Milestone revenue

-

-

-

-

10,000

2,000

2,000

1,500

Total revenue

-

-

-

-

66,729

8,576

25,408

12,849

Operating expenses:
Research and development

59,816

43,149

30,223

36,983

28,885

27,474

21,790

24,193

General and administrative

20,276

22,940

21,019

14,358

13,056

11,700

8,028

7,266

Total operating expenses

80,092

66,089

51,242

51,341

41,941

39,174

29,818

31,459

Loss from operations

-79,015

-55,584

92,649

-51,167

24,788

-30,598

-4,410

-18,610

Investment income

2,987

2,787

1,336

447

124

49

21

22

Other income

12

12

3,601

0

0

-

-

-

Interest and other expense

-

-

815

0

309

-

-

-

Interest and other expense

-

-

-

-

-

-1,150

-1,667

-1,856

Gain (Loss) on Extinguishment of Debt

-

-

-1,432

0

0

-

-

-

Unrealized loss on marketable equity securities

-2,150

-2,926

0

0

-

-

-

-

Income (Loss) before income taxes

-

-

-

-

24,603

-31,699

-6,056

-

Loss before income taxes

-78,166

-55,711

95,339

-50,720

-

-

-

-

Income Tax Expense (Benefit)

0

313

-300

0

429

0

0

-

Net Income (Loss) Attributable to Parent

-78,166

-56,024

95,639

-50,720

24,174

-31,699

-6,056

-20,444

Other comprehensive income:
Other comprehensive income:
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

106

270

-400

11

-4

-18

0

-5

Comprehensive loss

-78,060

-55,754

95,239

-50,709

-

-

-

-

Comprehensive income (loss)

-

-

-

-

24,170

-31,717

-6,056

-20,449

Net (loss) income

-78,166

-56,024

95,639

-50,720

24,174

-31,699

-6,056

-20,444

Accretion on redeemable convertible preferred stock

-

-

-

-

-

55

396

388

Net Income (Loss) Available to Common Stockholders, Basic

-

-

95,195

-50,720

24,174

-31,754

-6,452

-20,832

Net Income (Loss) Available to Common Stockholders, Diluted

-

-

95,210

-50,720

24,174

-

-

-

Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)

-3.29

-2.40

-

-

-

-

-

-16.15

Earnings Per Share, Basic

-

-

4.20

-2.28

1.14

-2.00

-4.99

-

Earnings Per Share, Diluted

-

-

4.06

-2.28

1.09

-2.00

-4.99

-

Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted (in shares)

23,740

23,370

-

-

-

-

-

1,290

Weighted Average Number of Shares Outstanding, Basic

-

-

22,641

22,233

21,152

15,842

1,292

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

23,442

22,233

22,267

15,842

1,292

-

License and research and development revenue
Total revenue

1,077

10,505

62

174

-

-

-

-

Product and Service, Other
Total revenue

-

-

143,829

0

-

-

-

-